Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck & Co. Inc. Add to portfolio

INX:MRK, Oct 23, 08:06 UTC

Latest INX:MRK News

Filter your feed

Apply Filter

Friday, October 19


News

Gonorrhea - Pipeline Review, H2 2018 Featuring Debiopharm International, Entasis Therapeutics, Merck & Co, Microbiotix and Recce - ResearchAndMarkets.com

MRK

Gonorrhea - Pipeline Review, H2 2018 Featuring Debiopharm International, Entasis Therapeutics, Merck & Co, Microbiotix and Recce - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Gonorrhea - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. Gonorrhea - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5 and 2 respectively.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Science

Wednesday, October 10


News

Global Contraceptive Market: Industry Analysis & Outlook (2018-2022) with Profiles for Bayer, Allergan, Merck & Co, and Teva Pharmaceuticals - ResearchAndMarkets.com

MRK BAYN +1 more MRK BAYN AGN

DUBLIN--(BUSINESS WIRE)--The "Global Contraceptive Market: Industry Analysis & Outlook (2018-2022)" report has been added to ResearchAndMarkets.com's offering. The global contraceptive market is experiencing a robust growth at a lucrative CAGR. Regionally, the U.S. is the major market for contraceptives due to its increasing female population of childbearing age, higher concentration of key companies, higher awareness of contraceptives and STDs infections, and increasing consumption of female condoms. Europe also holds a notable share in the global contraceptive market. However, its share can drop to some extent in future due to decreasing female population of reproductive ages.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Saturday, September 22


Social Chatter

Merck & Co. Inc. (INX:MRK) social chatter is higher than usual

MRK
.@Pfizer @Merck @JNJCares & @AbbottGlobal stash billion in profits offshore while charging sky-high prices for medicines, depriving women and girls of the opportunity to improve their lives and lift themselves out of poverty #NoMoreTaxDodging https://t.co/6SymQmp8d0

Wednesday, August 29


News

Global Travel Vaccines Market to 2025: Includes Profiles for Sanofi, Pfizer, GSK, Merck & Co, AstraZeneca, Abbott, Janssen, Roche, Takeda, and more - ResearchAndMarkets.com

SAN AZN +3 more SAN AZN MRK GSK AZN

Global Travel Vaccines Market to 2025: Includes Profiles for Sanofi, Pfizer, GSK, Merck & Co, AstraZeneca, Abbott, Janssen, Roche, Takeda, and more - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Global Travel Vaccines Market Analysis 2017 - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. Annual estimations and forecasts are provided from the year 2014 to 2025 for each given segment and sub segments. The report analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis.

Read Full Details

Topics:
  • Business
  • Financial

Saturday, August 04


News

Jacobs Levy Equity Management INC Has Cut Its Merck & Co INC (MRK) Position by $12.97 Million as Stock Value Rose

MRK MRK

Savings Bank Of Mellon has invested 0.53% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Sound Shore Incorporated Ct reported 4.70 million shares stake. And Invest Mgmt Grp Inc holds 1.91% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 108,986 shares. Jacobs Levy Equity Management Inc who had been investing in Merck & Co Inc for a number of months, seems to be less bullish one the $177.37B market cap company. Jacobs Levy Equity Management Inc, which manages about $10.42 billion and $6.01 billion US Long portfolio, upped its stake in M & T Bk Corp (NYSE:MTB) by 52,980 shares to 154,616 shares, valued at $28.51M in 2018Q1, according to the filing. More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: 247Wallst.com which released: “Merck Underwhelms Despite Beating Earnings” on July 27, 2018, also Benzinga.com with their article: “Merck Q2 Earnings Preview” published on July 26, 2018, Bizjournals.com published: “Alexandria’s Joel Marcus on Medicare-for-all, innovation and his company’s Peninsula plans” on August 03, 2018.

Read Full Details

Topics:
  • Business
  • Financial

Friday, July 27


News

Pyelonephritis: 2018 Pipeline Insights - featuring AstraZeneca, Merck & Co, Zavante Therapeutics, Achaogen, MerLion Pharmaceuticals, Rempex Pharmaceuticals and Zambon Group - ResearchAndMarkets.com

AZN MRK +1 more AZN MRK AZN

Pyelonephritis: 2018 Pipeline Insights - featuring AstraZeneca, Merck & Co, Zavante Therapeutics, Achaogen, MerLion Pharmaceuticals, Rempex Pharmaceuticals and Zambon Group - ResearchAndMarkets.com. DUBLIN--(BUSINESS WIRE)--The "Pyelonephritis - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Read Full Details

Topics:
  • Business
  • Health
  • Science
Social Chatter

Sunday, July 01


Social Chatter

Merck & Co. Inc. (INX:MRK) social chatter is higher than usual

MRK
Another reason to Impeach 45: He is unable to process simple facts & believes only what he wants to hear. Mental co… https://t.co/gzpAzbwemi

Sunday, June 17


News

D-E Shaw & Company INC Has Raised Its Merck & Co INC (MRK) Stake by $873.24 Million; Share Price Rose

MRK MRK

Hemenway Limited Liability has 0.54% invested in Merck & Co., Inc. (NYSE:MRK) for 52,044 shares. The hedge fund run by David Shaw held 16.43 million shares of the health care company at the end of 2018Q1, valued at $895.14 million, up from 262,500 at the end of the previous reported quarter. D-E Shaw & Company Inc who had been investing in Merck & Co Inc for a number of months, seems to be bullish on the $166.88B market cap company. D-E Shaw & Company Inc, which manages about $81.36B and $73.46B US Long portfolio, decreased its stake in Eog Res Inc (Put) (NYSE:EOG) by 82,100 shares to 23,200 shares, valued at $2.44M in 2018Q1, according to the filing.

Read Full Details

Topics:
  • Business
  • Financial

Wednesday, June 06


News

Drexel Morgan & Company Has Lowered Its Position in Merck & Co (MRK) as Share Value Rose; As Csx (CSX) Stock Price Rose, Valinor Management Lifted Stake

CSX MRK +3 more CSX MRK XOM RDSB RDSA

Drexel Morgan & Company Has Lowered Its Position in Merck & Co (MRK) as Share Value Rose; As Csx (CSX) Stock Price Rose, Valinor Management Lifted Stake. The hedge fund run by David Gallo held 1.85M shares of the railroads company at the end of 2018Q1, valued at $103.24 million, up from 652,000 at the end of the previous reported quarter. EXPAND MRNA CANCER VACCINES PACT; 16/04/2018 – BRISTOL-MYERS SQUIBB CO – SAFETY PROFILE FOR OPDIVO AT TWO-YEAR FOLLOW-UP WAS CONSISTENT WITH PREVIOUS ANALYSES FROM STUDY; 08/05/2018 – Merck & Co at Deutsche Bank Health Care Conference Tomorrow; 08/03/2018 – MERCK KGAA MRCG.DE CEO SAYS ARE PLEASED WITH INTEREST BY PROSPECTIVE BUYERS/PARTNERS; 03/04/2018 – EMA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA® (OLAPARIB) IN; 13/04/2018 – Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly; 08/03/2018 – TOKYO — Eisai said Thursday it has agreed to collaborate with U.S. counterpart Merck on development and marketing of the Japanese pharmaceutical company’s cancer drug Lenvima, a deal that also brings a timely infusion of cash; 27/03/2018 – Uptake of Merck KGaA’s Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals; 16/04/2018 – DYNAVAX INTERIM DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA® (; 23/05/2018 – THREE DEMOCRATIC REPUBLIC OF CONGO EBOLA PATIENTS ESCAPED QUARANTINE IN CITY OF MBANDAKA – MSF. Since May 2, 2018, it had 1 buying transaction, and 0 insider sales for $299,550 activity. It turned negative, as 79 investors sold CSX shares while 328 reduced holdings.

Read Full Details

Topics:
  • Business
  • Financial